FDA food advisory committee working group to discuss Ma Huang adverse events.
This article was originally published in The Tan Sheet
Executive Summary
MA HUANG SAFETY TO BE REVIEWED BY FDA FOOD ADVISORY COMMITTEE WORKING GROUP in a two-day meeting scheduled for Oct. 11-12. The agency publicly indicated its intention to review dietary supplements containing natural ephedra in a Sept. 21 Federal Register notice announcing the availability of adverse event reports related to "food products" containing ephedrine alkaloids. FDA said it has received over 300 ephedrine-related reports.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning